HIV treatment as prevention: Considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention

PLoS Medicine

Volumn 9, Issue 7, 2012, Pages

  Boily, Marie Claude ^a   Mâsse, Benoît ^b   Alsallaq, Ramzi ^c   Padian, Nancy S ^d,e   Eaton, Jeffrey W ^a   Vesga, Juan F ^a   Hallett, Timothy B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MONTREAL   (Canada)

^c NEW YORK UNIVERSITY   (United States)

^d U S DEPARTMENT OF STATE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CD4 LYMPHOCYTE COUNT; CONTAMINATION; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; INFECTION RISK; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; POPULATION EXPOSURE; PREVALENCE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL TRANSMISSION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS TRANSMISSION; BIOLOGICAL MODEL; CLUSTER ANALYSIS; DRUG COMBINATION;

ANTI-HIV AGENTS; CLUSTER ANALYSIS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864464463     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001250     Document Type: Review

References (54)

1. Joint United Nations Programme on HIV/AIDS (2011) World AIDS day report. How to get to zero: faster. smarter. better. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf. Accessed 25 November 2011.
2. Alliance for Microbicide Development (2009) HIV/STI prevention research and development: October 2009 pipeline update of microbicide and PrEP candidates. Available: http://www.microbicide.org/uploads/3/1/2/1/3121935/microbicide_pipeline_update_1_oct_2009.pdf. Accessed 31 December 2011.
3. US President's Emergency Plan for AIDS Relief (2011 August) Guidance for the prevention of sexually transmitted HIV infections. Available: http://www.pepfar.gov/documents/organization/171303.pdf. Accessed 2 January 2012.
4. Schwartlander B, Stover J, Hallett T, Atun R, Avila C, et al. (2011) Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 377: 2031-2041.
5. Boily MC, Abu-Raddad L, Desai K, Masse B, Self S, et al. (2008) Measuring the public-health impact of candidate HIV vaccines as part of the licensing process. Lancet Infect Dis 8: 200-207.
6. Boily MC, Desai K, Masse B, Gumel A, (2008) Incremental role of male circumcision on a generalised HIV epidemic through its protective effect against other sexually transmitted infections: from efficacy to effectiveness to population-level impact. Sex Transm Infect 84: ii28-ii34.
7. Brisson M, Edmunds WJ, (2003) Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 23: 76-82.
8. Donner A, Klar N, (2000) Design and analysis of cluster randomization trials in health research New York Oxford University Press.
9. US Department of State (2011 September 14) PEPFAR announces largest study of combination HIV prevention. Available: http://www.state.gov/r/pa/prs/ps/2011/09/172389.htm. Accessed 2 January 2012.
10. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, et al. (2011) Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 9: 446-469.
11. HIV Modelling Consortium, (2011) The potential impact of treatment on HIV incidence. Available: https://docs.google.com/viewer?a=v&pid=explorer&chrome=true&srcid=0B3AFjYLL-il3MGNhYjVkN2UtZmIwMy00ZWE4LWI4MDEtNTQ4NDVmNDNmYjRm&hl=en_US. Accessed 2 January 2012.
12. Padian NS, McCoy SI, Balkus JE, Wasserheit JN, (2010) Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 24: 621-635.
13. Boily MC, Lowndes CM, Vickerman P, Kumaranayake L, Blanchard J, et al. (2007) Evaluating large-scale HIV prevention interventions: study design for an integrated mathematical modelling approach. Sex Transm Infect 83: 582-589.
14. Korenromp EL, Van Vliet C, Grosskurth H, Gavyole A, Van der Ploeg CP, et al. (2000) Model-based evaluation of single-round mass treatment of sexually transmitted diseases for HIV control in a rural African population. AIDS 14: 573-593.
15. Boily MC, Lowndes CM, Alary M, (2000) Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda. AIDS 14: 2583-2592.
16. Hallett TB, Garnett GP, Mupamberiyi Z, Gregson S, (2008) Measuring effectiveness in community randomized trials of HIV prevention. Int J Epidemiol 37: 77-87.
17. Halloran ME, Struchiner CJ, (1991) Study designs for dependent happenings. Epidemiology 2: 331-338.
18. Halloran ME, (1998) Statistical issues in phase III human immunodeficiency virus vaccine trial design. J R Stat Soc Ser A Stat Soc 161: 265-272.
19. Alary M, Lowndes CM, Boily MC, (2003) Community randomized trials for HIV prevention: the past, a lesson for the future? AIDS 17: 2661-2663.
20. Boily MC, Masse BR, Desai K, Alary M, Anderson RM, (1999) Some important issues in the planning of phase III HIV vaccine efficacy trials. Vaccine 17: 989-1004.
21. Garnett GP, Cousens S, Hallett TB, Steketee R, Walker N, (2011) Mathematical models in the evaluation of health programmes. Lancet 378: 515-525.
22. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, et al. (2012) HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9: e1001245 doi:10.1371/journal.pmed.1001245.
23. Baggaley RF, Garnett GP, Ferguson NM, (2006) Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 3: e124 doi:10.1371/journal.pmed.0030124.
24. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
25. Johnstone-Robertson SP, Hargrove J, Williams BG, (2011) Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives? HIV AIDS (Auckl) 3: 9-17.
26. Alsallaq R, Baeten J, Hughes J, Abu-Raddad L, Celum C, et al. (2012) Modeling the potential impact of a combination prevention based on community-wide HIV testing: KwaZulu Natal, South Africa [abstract]. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, Washington, US. Available: http://www.retroconference.org/2012b/Abstracts/43187.htm. Accessed 31 May 2012.
27. Mehta SD, Gray RH, Auvert B, Moses S, Kigozi G, et al. (2009) Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials. AIDS 23: 1557-1564.
28. Cohen J, (2011) HIV prevention. Halting HIV/AIDS epidemics. Science 334: 1338-1340.
29. Boily MC, Pickles M, Vickerman P, Buzdugan R, Isac S, et al. (2008) Using mathematical modelling to investigate the plausibility of attributing observed antenatal clinic declines to a female sex worker intervention in Karnataka state, India. AIDS 22: S149-S164.
30. Vickerman P, Watts C, Delany S, Alary M, Rees H, et al. (2006) The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis 33: 397-405.
31. Dodd PJ, Garnett GP, Hallett TB, (2010) Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 24: 729-735.
32. Boily MC, Lowndes C, Alary M, (2002) The impact of HIV epidemic phases on the effectiveness of core group interventions: insights from mathematical models. Sex Transm Infect 78: i78-i90.
33. Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, et al. (2008) Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS ONE 3: e2212 doi:10.1371/journal.pone.0002212.
34. Grassly NC, Garnett GP, Schwartlander B, Gregson S, Anderson RM, (2001) The effectiveness of HIV prevention and the epidemiological context. Bull World Health Organ 79: 1121-1132.
35. Garnett GP, Anderson RM, (1993) Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Philos Trans R Soc Lond B Biol Sci 342: 137-159.
36. Robinson NJ, Mulder D, Auvert B, Whitworth J, Hayes R, (1999) Type of partnership and heterosexual spread of HIV infection in rural Uganda: results from simulation modelling. Int J STD AIDS 10: 718-725.
37. Eaton JW, Hallett TB, Garnett GP, (2011) Concurrent sexual partnerships and primary HIV infection: a critical interaction. AIDS Behav 15: 687-692.
38. Boily MC, Alary M, Baggaley RF, (2012) Neglected issues and hypotheses regarding the impact of sexual concurrency on HIV and sexually transmitted infections. AIDS Behav 16: 304-311.
39. Chen MI, Ghani AC, Edmunds J, (2008) Mind the gap: the role of time between sex with two consecutive partners on the transmission dynamics of gonorrhea. Sex Transm Dis 35: 435-444.
40. Mishra S, Vickerman P, Pickles M, Ramesh BM, Washington R, et al. (2011) HIV prevention based on the static modes of transmission synthesis for two Indian districts: insights from dynamical modeling [abstract]. 19th Biennial Conference of the International Society for Sexually Transmitted Diseases Research; 10-13 July 2011; Quebec City, Canada. doi:10.1136/sextrans-2011-050108.584.
41. Hayes RJ, Moulton LH, (2009) Cluster randomized trials. Chapman & Hall/CRC Interdisciplinary Statistics Series Boca Raton (Florida) CRC Press.
42. Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ, (2008) Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med 5: e50 doi:10.1371/journal.pmed.0050050.
43. Pickles M, Foss AM, Vickerman P, Deering K, Verma S, et al. (2010) Interim modelling analysis to validate reported increases in condom use and assess HIV infections averted among female sex workers and clients in southern India following a targeted HIV prevention programme. Sex Transm Infect 86: i33-i43.
44. Hallett TB, Gregson S, Mugurungi O, Gonese E, Garnett GP, (2009) Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. Epidemics 1: 108-117.
45. Blower S, Dowlatabadi H, (1994) Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 62: 229-243.
46. Johnson LF, Alkema L, Dorrington RE, (2010) A Bayesian approach to uncertainty analysis of sexually transmitted infection models. Sex Transm Infect 86: 169-174.
47. Desai K, Boily MC, Masse B, Anderson RM, (2006) Using transmission dynamics models to validate vaccine efficacy measures prior to conducting HIV vaccine efficacy trials. In: Abello J, Cormode G, editors. Discrete methods in epidemiology Providence (Rhode Island) American Mathematical Society pp. 139-163.
48. Emerson SS, Fleming TR, (2010) Adaptive methods: telling "the rest of the story" J Biopharm Stat 20: 1150-1165.
49. Hsu HS, Gupta G, (2010) An overview of the FDA draft guidance on adaptive design clinical trials [presentation]. MPCC Seminar Series. Available: http://www.fda.gov/downloads/BiologicsBloodVaccines/.../UCM209179.pdf. Accessed 16 March 2012.
50. Chow SC, Chang M, (2008) Adaptive design methods in clinical trials-a review. Orphanet J Rare Dis 3: 11.
51. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, et al. (2006) Adaptive designs in clinical drug development-an executive summary of the PhRMA Working Group. J Biopharm Stat 16: 275-283.
52. Zou GY, Donner A, Klar N, (2005) Group sequential methods for cluster randomization trials with binary outcomes. Clin Trials 2: 479-487.
53. Cook RJ, Lawless JF, (1996) Interim monitoring of longitudinal comparative studies with recurrent event responses. Biometrics 52: 1311-1323.
54. Meyer-Rath G, Over M, (2012) HIV treatment as prevention: modelling the cost of antiretroviral treatment-state of the art and future directions. PLoS Med 9: e1001247 doi:10.1371/journal.pmed.1001247.